Skip to main content
. Author manuscript; available in PMC: 2006 Sep 15.
Published in final edited form as: Clin Cancer Res. 2005 Sep 15;11(18):6657–6668. doi: 10.1158/1078-0432.CCR-04-2699

Fig. 2. Dose dependent cell-killing effect of Ad/TRAIL-F/RGD alone in human NSCLC cell lines but not in NHBE.

Fig. 2

A, Cell viability determined by the XTT assay in different cell lines at the fourth day after treated by Ad/TRAIL-F/RGD at MOIs range from 0 to3000VPs. B, Results of a flow cytometry analysis of transgene expression in a GFP cell population. Four cell lines were treated with Ad/g-TRAIL or Ad/CMV-GFP and harvested 2 days after treatment. Levels of GFP in the cells were determined by using fluorescence-activated cell sorting. C, Level of TRAIL expression in H1299 cells after treatment with different doses of Ad/TRAIL-F/RGD plus/minus radiation (5 Gy), as determined by Western blot analysis. β-actin was used as a loading control.